Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PRDM1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PRDM1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PRDM1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PRDM1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00017639 | Esophagus | ESCC | morphogenesis of a branching structure | 106/8552 | 196/18723 | 1.08e-02 | 3.66e-02 | 106 |
GO:00031703 | Esophagus | ESCC | heart valve development | 39/8552 | 65/18723 | 1.41e-02 | 4.59e-02 | 39 |
GO:00300984 | Esophagus | ESCC | lymphocyte differentiation | 192/8552 | 374/18723 | 1.52e-02 | 4.93e-02 | 192 |
GO:00165704 | Lung | IAC | histone modification | 93/2061 | 463/18723 | 5.41e-09 | 8.03e-07 | 93 |
GO:00715594 | Lung | IAC | response to transforming growth factor beta | 60/2061 | 256/18723 | 9.50e-09 | 1.25e-06 | 60 |
GO:00715604 | Lung | IAC | cellular response to transforming growth factor beta stimulus | 57/2061 | 250/18723 | 6.17e-08 | 6.54e-06 | 57 |
GO:00071794 | Lung | IAC | transforming growth factor beta receptor signaling pathway | 45/2061 | 198/18723 | 1.60e-06 | 7.93e-05 | 45 |
GO:00063256 | Lung | IAC | chromatin organization | 69/2061 | 409/18723 | 2.01e-04 | 3.53e-03 | 69 |
GO:00071785 | Lung | IAC | transmembrane receptor protein serine/threonine kinase signaling pathway | 60/2061 | 355/18723 | 4.82e-04 | 7.03e-03 | 60 |
GO:00454443 | Lung | IAC | fat cell differentiation | 42/2061 | 229/18723 | 6.19e-04 | 8.50e-03 | 42 |
GO:00349684 | Lung | IAC | histone lysine methylation | 25/2061 | 115/18723 | 6.35e-04 | 8.68e-03 | 25 |
GO:00182053 | Lung | IAC | peptidyl-lysine modification | 62/2061 | 376/18723 | 7.55e-04 | 9.82e-03 | 62 |
GO:00180223 | Lung | IAC | peptidyl-lysine methylation | 27/2061 | 131/18723 | 9.41e-04 | 1.14e-02 | 27 |
GO:19038444 | Lung | IAC | regulation of cellular response to transforming growth factor beta stimulus | 27/2061 | 131/18723 | 9.41e-04 | 1.14e-02 | 27 |
GO:00064794 | Lung | IAC | protein methylation | 34/2061 | 181/18723 | 1.28e-03 | 1.45e-02 | 34 |
GO:00082134 | Lung | IAC | protein alkylation | 34/2061 | 181/18723 | 1.28e-03 | 1.45e-02 | 34 |
GO:00165714 | Lung | IAC | histone methylation | 28/2061 | 141/18723 | 1.39e-03 | 1.53e-02 | 28 |
GO:00170153 | Lung | IAC | regulation of transforming growth factor beta receptor signaling pathway | 26/2061 | 128/18723 | 1.45e-03 | 1.55e-02 | 26 |
GO:0030512 | Lung | IAC | negative regulation of transforming growth factor beta receptor signaling pathway | 18/2061 | 81/18723 | 2.68e-03 | 2.46e-02 | 18 |
GO:0061647 | Lung | IAC | histone H3-K9 modification | 12/2061 | 48/18723 | 4.87e-03 | 3.77e-02 | 12 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PRDM1 | SNV | Missense_Mutation | | c.641N>C | p.Gly214Ala | p.G214A | O75626 | protein_coding | tolerated(0.05) | benign(0.003) | TCGA-A7-A0DA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
PRDM1 | SNV | Missense_Mutation | | c.1741G>A | p.Ala581Thr | p.A581T | O75626 | protein_coding | tolerated(0.4) | benign(0.007) | TCGA-A8-A06R-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR |
PRDM1 | SNV | Missense_Mutation | | c.1629C>A | p.Ser543Arg | p.S543R | O75626 | protein_coding | tolerated(0.4) | benign(0.034) | TCGA-A8-A09N-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
PRDM1 | SNV | Missense_Mutation | | c.709G>A | p.Glu237Lys | p.E237K | O75626 | protein_coding | tolerated(0.52) | benign(0.009) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PRDM1 | SNV | Missense_Mutation | | c.1735N>A | p.Val579Ile | p.V579I | O75626 | protein_coding | tolerated(0.33) | benign(0.023) | TCGA-AC-A6IW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PRDM1 | SNV | Missense_Mutation | novel | c.1288N>C | p.Ser430Arg | p.S430R | O75626 | protein_coding | deleterious(0.05) | benign(0.013) | TCGA-AN-A04D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PRDM1 | SNV | Missense_Mutation | | c.1047C>G | p.Ser349Arg | p.S349R | O75626 | protein_coding | tolerated(0.2) | benign(0.409) | TCGA-AN-A0AT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PRDM1 | SNV | Missense_Mutation | | c.461A>G | p.Glu154Gly | p.E154G | O75626 | protein_coding | deleterious(0.02) | possibly_damaging(0.502) | TCGA-B6-A0I9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
PRDM1 | SNV | Missense_Mutation | rs764666878 | c.2298N>C | p.Glu766Asp | p.E766D | O75626 | protein_coding | deleterious(0.04) | probably_damaging(0.96) | TCGA-BH-A42U-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PRDM1 | SNV | Missense_Mutation | | c.1850N>G | p.His617Arg | p.H617R | O75626 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-D8-A1JP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |